Table 1.

Molecular Genetic Testing Used in Hereditary Multiple Osteochondromas

Gene 1, 2Proportion of Hereditary Multiple Osteochondromas Attributed to Pathogenic Variants in GeneProportion of Probands with a Pathogenic Variant 3 Detectable by Method
Sequence analysis 4Gene-targeted deletion/
duplication analysis 5
EXT1 65%-70% 6, 7, 888%-93% 6, 87%-12% 6, 7
EXT2 30%-35% 6, 7, 8>90% 6, 8<10% 6, 7
Unknown10%-13% 9NA
1.

Genes are listed in alphabetic order.

2.

See Table A. Genes and Databases for chromosome locus and protein.

3.

See Molecular Genetics for information on variants detected in these genes.

4.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

5.

Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes may not be detected by these methods.

6.

Data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2017]; Pedrini et al [2011]; W Wuyts, personal communication

7.

Whole-gene, partial-gene, and single-exon deletions have been described but there are no recurrent break points [Jennes et al 2009, Jennes et al 2011, Li et al 2019].

8.
9.

It is suspected that simplex cases of HMO harbor a somatic EXT1 or EXT2 pathogenic variant not detected by standard protocols performed on DNA isolated from whole blood samples due to limits of detection [Szuhai et al 2011].

From: Hereditary Multiple Osteochondromas

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.